A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that damages blood vessels in the light-sensitive retina in the back of the eye. Lucentis is used to treat wet macular degeneration as well as diabetic macula edema. The study found the treatment no less effective than the laser therapy which currently is the standard treatment for PDR.
In a RPB-supported commentary, Timothy W. Olsen, MD, notes that "this important study [...] represents a major step forward for patients with PDR by providing the ophthalmologists who manage their retinal disease with new options." But he adds a cautionary note.
November 17, 2015
The existence of the National Eye Institute, the most important source of funding for vision research in the U.S., is being threatened.
The ARPA-H THEA project takes on an exciting challenge.
The awards offered cover a wide variety of topics in vision science, including glaucoma, age-related macular degeneration, retinal diseases, and many more.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |